AVEO Oncology Highlights Recent Progress and 2022 Outlook :

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted...

Related Keywords

United States , Germany , Boston , Massachusetts , American , Fotivda Tivozanib Sm , Michael Bailey , Fotivda Tivozanib , Hans Vitzthum , Kevin Cullen , Bristol Myers Squibb , American Society Of Clinical Oncology , Pharma United Kingdom , Nasdaq , Merck Kga , Astrazeneca , Us Commercialization Team , Program In Oncology , University Of Maryland School Medicine , European Union , Pharmaceuticals Inc , Stewart Greenebaum Comprehensive Cancer Center , American Cancer Society , Lifesci Advisors , Horizon Discovery Group , Drug Administration , University Of Maryland Marlene , Key Recent Program Updates , Exchange Commission , Merck Kgaa , Hercules Capital Inc , Chief Executive Officer , American Society , Clinical Oncology , Fast Track , Recent Program Updates , Fast Track Designation , Stewart Greenebaum Distinguished Professor , Maryland School , Maryland Marlene , Stewart Greenebaum Comprehensive Cancer , Ledell Appointed , Chief Operating , Enzyvant Therapeutics , Compass Therapeutics , Hercules Capital , Performance Milestone , United Kingdom , Hypertensive Crisis , Arterial Thromboembolic Events , Thromboembolic Events , Impaired Wound Healing , Posterior Leukoencephalopathy Syndrome , Fetal Toxicity , Reproductive Potential , Prescribing Information , Private Securities Litigation Reform Act , Factor Summary , Financial Condition , Clin Oncol , Sci Advisors , Nasdaq Aveo , Aveo Pharmaceuticals , Nc ,